Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7672309 | 1.00 | SLC10A2 (0.44) | SLC10A2 | |
| SCHEMBL22286375 | 0.96 | SLC10A2 (0.43) | SLC10A2 | |
| SCHEMBL8015441 | 0.92 | SLC10A2 (0.48) | SLC10A2 | |
| SCHEMBL30728266 | 0.89 | SLC10A2 (0.44) | SLC10A2 | |
| SCHEMBL21586084 | 0.89 | SLC10A2 (0.44) | SLC10A2 | |
| SCHEMBL3815126 | 0.89 | SLC10A2 (0.44) | SLC10A2 | |
| SCHEMBL21585949 | 0.89 | SLC10A2 (0.44) | SLC10A2 | |
| SCHEMBL25622370 | 0.89 | SLC10A2 (0.44) | SLC10A2 | |
| SCHEMBL27118537 | 0.88 | SLC10A2 (0.51) | SLC10A2 | |
| SCHEMBL21585898 | 0.87 | SLC10A2 (0.42) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6465451-B1 | Hypolipidemic benzothiazepine compounds | SMITHKLINE BEECHAM CORPORATION | 2002-10-15 | — | — | US | claimed |
| CN-118834175-A | Benzothiazacycloalkanes Heptatriene compounds use thereof as bile acid modulators | 阿尔比里奥公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-113453753-B | Benzothiazepine compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-112449637-B | Benzothiazepine compounds and their use as bile acid modulators | 阿尔比里奥公司 | 2024-03-19 | — | — | CN | disclosed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2023-10-03 | — | — | US | disclosed |
| EP-3921027-B1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-07-19 | — | — | EP | disclosed |
| EP-3921027-B1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-07-19 | — | — | EP | disclosed |
| EP-3802504-B1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2023-01-18 | — | — | EP | disclosed |
| US-10793534-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | ALBIREO AB (SE) | 2020-10-06 | — | — | US | disclosed |
| WO-2020161216-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020161216-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-06 | — | — | US | disclosed |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2020-08-06 | — | — | US | disclosed |
| WO-2019234077-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2019-12-12 | — | — | WO | disclosed |
| WO-2019234077-A1 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | ALBIREO AB (SE) | 2019-12-12 | — | — | WO | disclosed |
| US-6465451-B1 | Hypolipidemic benzothiazepine compounds | SMITHKLINE BEECHAM CORPORATION | 2002-10-15 | — | — | US | disclosed |
| EP-1045840-A1 | HYPOLIPIDEMIC BENZOTHIAZEPINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035135-A1 | HYPOLIPIDEMIC BENZOTHIAZEPINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773071-B2 | Benzothiazepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
| US-10793534-B2 | Benzothia(di)azepine compounds and their use as bile acid modulators | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
| US-20200247768-A1 | BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | SLC10A1, SLC10A2, ABCB11 | SLC10A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.